TRG inhibited Nrf2 activation and nuclear translocation in non-small cell lung cancer (NSCLC), inhibiting the EGFR signaling pathway and its downstream effector ERK 1/2 kinase [58]. Here, NFE2L2 is linked to non-small cell lung carcinoma.